Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novartis Lining Up More Potent COVID-19 Antiviral Pills Rivaling Merck, Pfizer

09/28/2021 | 09:09am EDT


ę MT Newswires 2021
All news about MERCK & CO., INC.
10:34aMERCK : And Co. Gets European Medicines Agency's Positive Opinions on Pneumonia Vaccine, C..
MT
08:55aMERCK : Receives Positive Opinions From European Medicines Agency on Pneumonia Vaccine, Ca..
MT
08:07aMerck, Eisai Get CHMP Backing for Lenvima-Keytruda Combo in Two Cancers
DJ
07:21aMERCK : and Eisai Receive Positive EU CHMP Opinions for KEYTRUDA« (pembrolizumab) Plus LEN..
BU
07:16aMERCK : Receives Positive CHMP Opinion for VAXNEUVANCE™ (Pneumococcal 15-valent Conj..
BU
06:13aMerck Gets CHMP Positive Opinion for Vaxneuvance Vaccine
DJ
12:17aMERCK : US FDA To Review Merck & Co.'s COVID-19 Antiviral Drug For Approval In Late Novemb..
MT
10/14MERCK : FDA to Review Merck's Emergency Use Authorization Request For Molnupiravir COVID-1..
MT
10/14MERCK : Nov 30th FDA Advisory Committee meeting to Discuss Merck & Ridgeback's COVID-19 An..
MT
10/14MERCK : Acceleron Pharma Shareholder Says Merck & Co.'s Offer Significantly Undervalues Co..
MT
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Financials (USD)
Sales 2021 48 042 M - -
Net income 2021 13 209 M - -
Net Debt 2021 17 557 M - -
P/E ratio 2021 16,5x
Yield 2021 3,31%
Capitalization 198 B 198 B -
EV / Sales 2021 4,49x
EV / Sales 2022 3,98x
Nbr of Employees 73 500
Free-Float 70,7%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Last Close Price 78,33 $
Average target price 95,16 $
Spread / Average Target 21,5%
EPS Revisions
Managers and Directors
Robert M. Davis President, Chief Executive Officer & Director
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Kenneth C. Frazier Executive Chairman
Sandy Tremps Vice President-R&D IT CIO
Dave Williams Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.-4.24%198 283
JOHNSON & JOHNSON2.49%421 487
ROCHE HOLDING AG15.58%336 383
PFIZER, INC.13.20%233 631
NOVO NORDISK A/S51.58%230 493
ELI LILLY AND COMPANY40.89%214 579